Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density.
Due to the COVID-19 pandemic, the global Postmenopausal Osteoporosis Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Postmenopausal Osteoporosis Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Postmenopausal Osteoporosis Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years.
This report focuses on Postmenopausal Osteoporosis Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Postmenopausal Osteoporosis Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Postmenopausal Osteoporosis Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Antiresorptive Medications
Anabolic Medications
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Eli Lilly
Amgen
Merck
Novartis
Allergan
Amgen Astellas Biopharm
Deltanoid Pharmaceuticals
Noven
Novo Nordisk
Osteologix
Pfizer
PhytoHealth
Radius Health
Tarsa Therapeutics
